dry eye disease - Spark Newswire

1 minute read

Aldeyra’s Dry Eye Disease Trial Meets Primary Endpoint, But Misses On Secondary Endpoint

November 2, 12:44 PM

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease.

ALDX

1 minute read

FDA Approves First Nasal Spray For Dry Eye Disease From Oyster Point Pharma

By Vandana Singh

October 18, 5:36 PM

The FDA has approved Oyster Point Pharma Inc (NASDAQ:OYST) Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for signs and symptoms of…

OYST

1 minute read

FDA Approves First Nasal Spray For Dry Eye Disease From Oyster Point Pharma

By Vandana Singh

October 18, 5:36 PM

The FDA has approved Oyster Point Pharma Inc (NASDAQ:OYST) Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for signs and symptoms of…

OYST

1 minute read

Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial

By Vandana Singh

September 16, 5:59 AM

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced topline results of its Phase 2b COMET-1 study evaluating AR-15512 (TRPM8 Agonist) ophthalmic solution for dry…

AERI

1 minute read

Oyster Point Inks License Pact With Ji Xing Pharma For Dry Eye Disease Candidates In Greater China

By Vandana Singh

August 6, 10:12 AM

Oyster Point Pharma Inc (NASDAQ:OYST) has announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline)…

OYST